Obinutuzumab

Obinutuzumab is a glycoengineered, type II anti-CD20 monoclonal antibody (more potent B-cell depletion than rituximab in oncology settings) that is not established as standard therapy for idiopathic inflammatory myopathies (IIM) but is increasingly discussed as an off-label rescue option when B-cell targeting is desired and rituximab is ineffective or not tolerated—particularly in antisynthetase-spectrum disease and severe ILD phenotypes.

The IIM evidence base is limited to small observational data: an ACR 2024 retrospective case series (n=5 refractory IIM; including antisynthetase, dermatomyositis, and overlap myositis) reported clinician-assessed improvement across muscle/skin/lung/joint domains within ~3–6 months, steroid reduction in several cases, and no major infections in that small cohort, supporting a signal rather than proof.

Additional support comes from case-based literature and connective-tissue disease experience after rituximab non-response, including patients with prominent myositis/ILD manifestations. Most recently, an Annals of the Rheumatic Diseases report described two rituximab-refractory IIM cases with severe ILD treated with obinutuzumab (no abstract available on PubMed), reinforcing the “refractory ILD” niche but still leaving major uncertainties about magnitude of benefit, optimal dosing/redosing, and predictors of response.

https://ard.eular.org/article/S0003-4967(25)04236-0/abstract

Safety considerations are nontrivial and should be handled like other anti-CD20 therapy: the FDA label carries boxed warnings for hepatitis B reactivation and progressive multifocal leukoencephalopathy (PML), and common risks include infusion reactions, neutropenia, and serious infections—so HBV screening/monitoring and infection risk stratification are mandatory in any off-label IIM use.